Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 147

1.

Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma (NVUC).

Weyerer V, Weisser R, Moskalev EA, Haller F, Stoehr R, Eckstein M, Zinnall U, Gaisa NT, Compérat E, Perren A, Keck B, Allory Y, Kristiansen G, Wullich B, Agaimy A, Hartmann A, Bertz S.

Histopathology. 2019 Jul 26. doi: 10.1111/his.13958. [Epub ahead of print]

PMID:
31348552
2.

The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes.

Pfannstiel C, Strissel PL, Chiappinelli KB, Sikic D, Wach S, Wirtz RM, Wullweber A, Taubert H, Breyer J, Otto W, Worst T, Burger M, Wullich B, Bolenz C, Fuhrich N, Geppert CI, Weyerer V, Stoehr R, Bertz S, Keck B, Erlmeier F, Erben P, Hartmann A, Strick R, Eckstein M; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany.

Cancer Immunol Res. 2019 Jun;7(6):923-938. doi: 10.1158/2326-6066.CIR-18-0758. Epub 2019 Apr 15.

PMID:
30988029
3.

Multiregion human bladder cancer sequencing reveals tumour evolution, bladder cancer phenotypes and implications for targeted therapy.

Heide T, Maurer A, Eipel M, Knoll K, Geelvink M, Veeck J, Knuechel R, van Essen J, Stoehr R, Hartmann A, Altmueller J, Graham TA, Gaisa NT.

J Pathol. 2019 Jun;248(2):230-242. doi: 10.1002/path.5250. Epub 2019 Mar 18.

PMID:
30719704
4.

No Evidence of Microsatellite Instability and Loss of Mismatch-Repair-Protein Expression in Squamous Cell Carcinoma of the Penis.

Stoehr R, Wendler O, Giedl J, Gaisa NT, Richter G, Campean V, Burger M, Wullich B, Bertz S, Hartmann A.

Pathobiology. 2019;86(2-3):145-151. doi: 10.1159/000495251. Epub 2019 Jan 16.

PMID:
30650417
5.

Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab.

Eckstein M, Erben P, Kriegmair MC, Worst TS, Weiß CA, Wirtz RM, Wach S, Stoehr R, Sikic D, Geppert CI, Weyerer V, Bertz S, Breyer J, Otto W, Keck B, Burger M, Taubert H, Weichert W, Wullich B, Bolenz C, Hartmann A, Erlmeier F.

Eur J Cancer. 2019 Jan;106:234-243. doi: 10.1016/j.ejca.2018.11.007. Epub 2018 Dec 5.

PMID:
30528808
6.

P53 Codon 72 Polymorphism and Risk for Squamous Cell Carcinoma of the Penis: A Caucasian Case-Control Study.

Stoehr R, Weisser R, Wendler O, Giedl J, Daifalla K, Gaisa NT, Richter G, Campean V, Burger M, Wullich B, Hartmann A.

J Cancer. 2018 Oct 20;9(22):4234-4241. doi: 10.7150/jca.26050. eCollection 2018.

7.

mRNA-Expression of KRT5 and KRT20 Defines Distinct Prognostic Subgroups of Muscle-Invasive Urothelial Bladder Cancer Correlating with Histological Variants.

Eckstein M, Wirtz RM, Gross-Weege M, Breyer J, Otto W, Stoehr R, Sikic D, Keck B, Eidt S, Burger M, Bolenz C, Nitschke K, Porubsky S, Hartmann A, Erben P.

Int J Mol Sci. 2018 Oct 30;19(11). pii: E3396. doi: 10.3390/ijms19113396.

8.

FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer.

Breyer J, Wirtz RM, Erben P, Rinaldetti S, Worst TS, Stoehr R, Eckstein M, Sikic D, Denzinger S, Burger M, Hartmann A, Otto W.

BJU Int. 2019 Jan;123(1):187-196. doi: 10.1111/bju.14525. Epub 2018 Sep 9.

PMID:
30120861
9.

Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype.

Zinnall U, Weyerer V, Compérat E, Camparo P, Gaisa NT, Knuechel-Clarke R, Perren A, Lugli A, Toma M, Baretton G, Kristiansen G, Wirtz RM, Cheng L, Wullich B, Stoehr R, Hartmann A, Bertz S.

Hum Pathol. 2018 Oct;80:55-64. doi: 10.1016/j.humpath.2018.05.022. Epub 2018 Jun 6.

10.

Metric substage according to micro and extensive lamina propria invasion improves prognostics in T1 bladder cancer.

Fransen van de Putte EE, Otto W, Hartmann A, Bertz S, Mayr R, Bründl J, Breyer J, Manach Q, Compérat EM, Boormans JL, Bosschieter J, Jewett MAS, Stoehr R, van Leenders GJLH, Nieuwenhuijzen JA, Zlotta AR, Hendricksen K, Rouprêt M, Burger M, van der Kwast TH, van Rhijn BWG.

Urol Oncol. 2018 Aug;36(8):361.e7-361.e13. doi: 10.1016/j.urolonc.2018.05.007. Epub 2018 Jun 5.

PMID:
29880460
11.

Intraductal Papillary Mucinous Neoplasms of Minor Salivary Glands With AKT1 p.Glu17Lys Mutation.

Agaimy A, Mueller SK, Bumm K, Iro H, Moskalev EA, Hartmann A, Stoehr R, Haller F.

Am J Surg Pathol. 2018 Aug;42(8):1076-1082. doi: 10.1097/PAS.0000000000001080.

PMID:
29738361
12.

The World Health Organization 1973 classification system for grade is an important prognosticator in T1 non-muscle-invasive bladder cancer.

van de Putte EEF, Bosschieter J, van der Kwast TH, Bertz S, Denzinger S, Manach Q, Compérat EM, Boormans JL, Jewett MAS, Stoehr R, van Leenders GJLH, Nieuwenhuijzen JA, Zlotta AR, Hendricksen K, Rouprêt M, Otto W, Burger M, Hartmann A, van Rhijn BWG.

BJU Int. 2018 Dec;122(6):978-985. doi: 10.1111/bju.14238. Epub 2018 Apr 27.

PMID:
29637669
13.

A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy.

Eckstein M, Wirtz RM, Pfannstil C, Wach S, Stoehr R, Breyer J, Erlmeier F, Günes C, Nitschke K, Weichert W, Otto W, Keck B, Eidt S, Burger M, Taubert H, Wullich B, Bolenz C, Hartmann A, Erben P.

Oncotarget. 2018 Feb 19;9(19):15001-15014. doi: 10.18632/oncotarget.24531. eCollection 2018 Mar 13.

14.

High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma.

Breyer J, Wirtz RM, Erben P, Worst TS, Stoehr R, Eckstein M, Bertz S, Sikic D, Denzinger S, Burger M, Hartmann A, Otto W; Bladder Cancer Research Initiative for Drug Targets Germany (BRIDGE) Consortium eV, Mannheim, Germany.

Clin Genitourin Cancer. 2018 Aug;16(4):248-256.e2. doi: 10.1016/j.clgc.2018.01.009. Epub 2018 Feb 2.

PMID:
29525349
15.

Rathke's Cleft Cyst as Origin of a Pediatric Papillary Craniopharyngioma.

Schlaffer SM, Buchfelder M, Stoehr R, Buslei R, Hölsken A.

Front Genet. 2018 Feb 22;9:49. doi: 10.3389/fgene.2018.00049. eCollection 2018.

16.

Diagnostic potential of major and trace elements in the serum of bladder cancer patients.

Wach S, Weigelt K, Michalke B, Lieb V, Stoehr R, Keck B, Hartmann A, Wullich B, Taubert H, Chaudhri A.

J Trace Elem Med Biol. 2018 Mar;46:150-155. doi: 10.1016/j.jtemb.2017.12.010. Epub 2017 Dec 28.

PMID:
29413105
17.

High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients.

Breyer J, Wirtz RM, Otto W, Erben P, Worst TS, Stoehr R, Eckstein M, Denzinger S, Burger M, Hartmann A.

Cancer Immunol Immunother. 2018 Mar;67(3):403-412. doi: 10.1007/s00262-017-2093-9. Epub 2017 Nov 17.

PMID:
29150702
18.

Predictive value of molecular subtyping in NMIBC by RT-qPCR of ERBB2, ESR1, PGR and MKI67 from formalin fixed TUR biopsies.

Breyer J, Wirtz RM, Otto W, Laible M, Schlombs K, Erben P, Kriegmair MC, Stoehr R, Eidt S, Denzinger S, Burger M, Hartmann A.

Oncotarget. 2017 Jun 28;8(40):67684-67695. doi: 10.18632/oncotarget.18804. eCollection 2017 Sep 15.

19.

Wntless promotes bladder cancer growth and acts synergistically as a molecular target in combination with cisplatin.

Schmid SC, Sathe A, Guerth F, Seitz AK, Heck MM, Maurer T, Schwarzenböck SM, Krause BJ, Schulz WA, Stoehr R, Gschwend JE, Retz M; German Bladder Cancer Network, Nawroth R.

Urol Oncol. 2017 Sep;35(9):544.e1-544.e10. doi: 10.1016/j.urolonc.2017.04.015. Epub 2017 May 10.

PMID:
28501564
20.

An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper®.

Varga Z, Lebeau A, Bu H, Hartmann A, Penault-Llorca F, Guerini-Rocco E, Schraml P, Symmans F, Stoehr R, Teng X, Turzynski A, von Wasielewski R, Gürtler C, Laible M, Schlombs K, Joensuu H, Keller T, Sinn P, Sahin U, Bartlett J, Viale G.

Breast Cancer Res. 2017 May 11;19(1):55. doi: 10.1186/s13058-017-0848-z.

21.

Immunohistochemical and molecular characterizations in urothelial carcinoma of bladder in patients less than 45 years.

Weyerer V, Schneckenpointner R, Filbeck T, Burger M, Hofstaedter F, Wild PJ, Fine SW, Humphrey PA, Dehner LP, Amin MB, Rüschoff J, Boltze C, Tannapfel A, Zwarthoff E, Lopez-Beltran A, Montironi R, Langner C, Stoehr R, Hartmann A, Giedl J.

J Cancer. 2017 Feb 5;8(3):323-331. doi: 10.7150/jca.17482. eCollection 2017.

22.

In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival.

Breyer J, Wirtz RM, Otto W, Erben P, Kriegmair MC, Stoehr R, Eckstein M, Eidt S, Denzinger S, Burger M, Hartmann A; BRIDGE Consortium.

Virchows Arch. 2017 Mar;470(3):267-274. doi: 10.1007/s00428-017-2064-8. Epub 2017 Jan 10.

PMID:
28074276
23.

ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situ.

Breyer J, Otto W, Wirtz RM, Wullich B, Keck B, Erben P, Kriegmair MC, Stoehr R, Eckstein M, Laible M, Schlombs K, Eidt S, Denzinger S, Burger M, Hartmann A; BRIDGE Consortium.

Urol Int. 2017;98(3):282-289. doi: 10.1159/000453670. Epub 2016 Dec 17.

PMID:
27992871
24.

ESR1, ERBB2, and Ki67 mRNA expression predicts stage and grade of non-muscle-invasive bladder carcinoma (NMIBC).

Breyer J, Wirtz RM, Laible M, Schlombs K, Erben P, Kriegmair MC, Stoehr R, Eidt S, Denzinger S, Burger M, Hartmann A, Otto W.

Virchows Arch. 2016 Nov;469(5):547-552. Epub 2016 Aug 11.

PMID:
27514658
25.

Fibroblast growth factor receptor (FGFR) alterations in squamous differentiated bladder cancer: a putative therapeutic target for a small subgroup.

Baldia PH, Maurer A, Heide T, Rose M, Stoehr R, Hartmann A, Williams SV, Knowles MA, Knuechel R, Gaisa NT.

Oncotarget. 2016 Nov 1;7(44):71429-71439. doi: 10.18632/oncotarget.12198.

26.

TERT Core Promotor Mutations in Early-Onset Bladder Cancer.

Giedl J, Rogler A, Wild A, Riener MO, Filbeck T, Burger M, Rümmele P, Hurst C, Knowles M, Hartmann A, Zinnall U, Stoehr R.

J Cancer. 2016 May 7;7(8):915-20. doi: 10.7150/jca.15006. eCollection 2016.

27.

The Microphthalmia-Associated Transcription Factor p.E318K Mutation Does Not Play a Major Role in Sporadic Renal Cell Tumors from Caucasian Patients.

Stoehr CG, Walter B, Denzinger S, Ghiorzo P, Sturm RA, Hinze R, Moch H, Junker K, Hartmann A, Stoehr R.

Pathobiology. 2016;83(4):165-9. doi: 10.1159/000443311. Epub 2016 Mar 22.

28.

Homozygous G/G variant of SNP309 in the human MDM2 gene is associated with earlier tumor onset in Caucasian female renal cell carcinoma patients.

Stoehr CG, Stoehr R, Wenners A, Hartmann A, Bertz S, Spath V, Walter B, Junker K, Moch H, Hinze R, Denzinger S, Bond EE, Bond GL, Bluemke K, Weigelt K, Lieb V, Nolte E, Fornara P, Wullich B, Taubert H, Wach S.

Oncogenesis. 2016 Feb 29;5:e205. doi: 10.1038/oncsis.2016.15.

29.

Metastatic Malignant Melanoma With Complete Loss of Differentiation Markers (Undifferentiated/Dedifferentiated Melanoma): Analysis of 14 Patients Emphasizing Phenotypic Plasticity and the Value of Molecular Testing as Surrogate Diagnostic Marker.

Agaimy A, Specht K, Stoehr R, Lorey T, Märkl B, Niedobitek G, Straub M, Hager T, Reis AC, Schilling B, Schneider-Stock R, Hartmann A, Mentzel T.

Am J Surg Pathol. 2016 Feb;40(2):181-91. doi: 10.1097/PAS.0000000000000527.

PMID:
26448190
30.

FoxO1 regulates asymmetric dimethylarginine via downregulation of dimethylaminohydrolase 1 in human endothelial cells and subjects with atherosclerosis.

Menghini R, Casagrande V, Cardellini M, Ballanti M, Davato F, Cardolini I, Stoehr R, Fabrizi M, Morelli M, Anemona L, Bernges I, Schwedhelm E, Ippoliti A, Mauriello A, Böger RH, Federici M.

Atherosclerosis. 2015 Sep;242(1):230-5. doi: 10.1016/j.atherosclerosis.2015.07.026. Epub 2015 Jul 16.

PMID:
26226438
31.

The situation of former adolescent self-injurers as young adults: a follow-up study.

Groschwitz RC, Plener PL, Kaess M, Schumacher T, Stoehr R, Boege I.

BMC Psychiatry. 2015 Jul 18;15:160. doi: 10.1186/s12888-015-0555-1.

32.

Piwil 2 expression is correlated with disease-specific and progression-free survival of chemotherapy-treated bladder cancer patients.

Taubert H, Wach S, Jung R, Pugia M, Keck B, Bertz S, Nolte E, Stoehr R, Lehmann J, Ohlmann CH, Stöckle M, Wullich B, Hartmann A.

Mol Med. 2015 May 13;21:371-80. doi: 10.2119/molmed.2014.00250.

33.

Frequency of TERT Promoter Mutations in Prostate Cancer.

Stoehr R, Taubert H, Zinnall U, Giedl J, Gaisa NT, Burger M, Ruemmele P, Hurst CD, Knowles MA, Wullich B, Hartmann A.

Pathobiology. 2015;82(2):53-7. doi: 10.1159/000381903. Epub 2015 May 21.

34.

Functional analyses and prognostic significance of SFRP1 expression in bladder cancer.

Rogler A, Kendziorra E, Giedl J, Stoehr C, Taubert H, Goebell PJ, Wullich B, Stöckle M, Lehmann J, Petsch S, Hartmann A, Stoehr R.

J Cancer Res Clin Oncol. 2015 Oct;141(10):1779-90. doi: 10.1007/s00432-015-1942-1. Epub 2015 Mar 4.

PMID:
25732201
35.

Identification and diagnostic performance of a small RNA within the PCA3 and BMCC1 gene locus that potentially targets mRNA.

Drayton RM, Rehman I, Clarke R, Zhao Z, Pang K, Miah S, Stoehr R, Hartmann A, Blizard S, Lavin M, Bryant HE, Martens-Uzunova ES, Jenster G, Hamdy FC, Gardiner RA, Catto JW.

Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):268-75. doi: 10.1158/1055-9965.EPI-14-0377. Epub 2014 Nov 12.

36.

Speckle-type POZ protein mutations in prostate cancer: a new part of the mosaic.

Stoehr R.

Asian J Androl. 2015 Jan-Feb;17(1):161. doi: 10.4103/1008-682X.140965. No abstract available.

37.

Increased angiogenesis and FGFR protein expression indicate a favourable prognosis in bladder cancer.

Bertz S, Abeé C, Schwarz-Furlan S, Alfer J, Hofstädter F, Stoehr R, Hartmann A, Gaumann AK.

Virchows Arch. 2014 Dec;465(6):687-95. doi: 10.1007/s00428-014-1672-9. Epub 2014 Oct 19.

PMID:
25326864
38.

Low frequency of HNPCC-associated microsatellite instability and aberrant MMR protein expression in early-onset bladder cancer.

Giedl J, Schneckenpointner R, Filbeck T, Ruemmele P, Hofstaedter F, Burger M, Hartmann A, Stoehr R.

Am J Clin Pathol. 2014 Nov;142(5):634-9. doi: 10.1309/AJCPVTCJ4VU5HKVZ.

PMID:
25319978
39.

Pancreatic undifferentiated rhabdoid carcinoma: KRAS alterations and SMARCB1 expression status define two subtypes.

Agaimy A, Haller F, Frohnauer J, Schaefer IM, Ströbel P, Hartmann A, Stoehr R, Klöppel G.

Mod Pathol. 2015 Feb;28(2):248-60. doi: 10.1038/modpathol.2014.100. Epub 2014 Aug 8.

40.

Comparative genomic hybridization shows complex genomic changes of plasmacytoid urothelial carcinoma.

Keck B, Ellmann C, Stoehr R, Weigelt K, Goebell PJ, Kunath F, Taubert H, Hartmann A, Wullich B, Wach S.

Urol Oncol. 2014 Nov;32(8):1234-9. doi: 10.1016/j.urolonc.2014.06.016. Epub 2014 Jul 30.

PMID:
25087089
41.

Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer.

Fischbach A, Rogler A, Erber R, Stoehr R, Poulsom R, Heidenreich A, Schneevoigt BS, Hauke S, Hartmann A, Knuechel R, Veeck J, Gaisa NT.

Histopathology. 2015 Apr;66(5):639-49. doi: 10.1111/his.12473. Epub 2015 Jan 12.

PMID:
24898159
42.

Adult type granulosa cell tumor of the testis with a heterologous sarcomatous component: case report and review of the literature.

Schubert TE, Stoehr R, Hartmann A, Schöne S, Löbelenz M, Mikuz G.

Diagn Pathol. 2014 Jun 3;9:107. doi: 10.1186/1746-1596-9-107. Review.

43.

Frequency of activating mutations in FGFR2 exon 7 in bladder tumors from patients with early-onset and regular-onset disease.

Spiegelberg C, Giedl J, Gaisa NT, Rogler A, Riener MO, Filbeck T, Burger M, Ruemmele P, Hartmann A, Stoehr R.

Int J Clin Exp Pathol. 2014 Mar 15;7(4):1708-13. eCollection 2014.

44.

[Prognostic and predictive molecular markers for urologic cancers].

Hartmann A, Schlomm T, Bertz S, Heinzelmann J, Hölters S, Simon R, Stoehr R, Junker K.

Urologe A. 2014 Apr;53(4):491-500. doi: 10.1007/s00120-014-3442-3. Review. German.

PMID:
24700189
45.

Loss of MTUS1/ATIP expression is associated with adverse outcome in advanced bladder carcinomas: data from a retrospective study.

Rogler A, Hoja S, Giedl J, Ekici AB, Wach S, Taubert H, Goebell PJ, Wullich B, Stöckle M, Lehmann J, Petsch S, Hartmann A, Stoehr R.

BMC Cancer. 2014 Mar 20;14:214. doi: 10.1186/1471-2407-14-214.

46.

SMARCB1 (INI1)-negative rhabdoid carcinomas of the gastrointestinal tract: clinicopathologic and molecular study of a highly aggressive variant with literature review.

Agaimy A, Rau TT, Hartmann A, Stoehr R.

Am J Surg Pathol. 2014 Jul;38(7):910-20. doi: 10.1097/PAS.0000000000000173. Review.

PMID:
24503755
47.

MiR-216a: a link between endothelial dysfunction and autophagy.

Menghini R, Casagrande V, Marino A, Marchetti V, Cardellini M, Stoehr R, Rizza S, Martelli E, Greco S, Mauriello A, Ippoliti A, Martelli F, Lauro R, Federici M.

Cell Death Dis. 2014 Jan 30;5:e1029. doi: 10.1038/cddis.2013.556.

48.

Mdm2 SNP309 G-variant is associated with invasive growth of human urinary bladder cancer.

Hitzenbichler F, Stoehr CG, Rogenhofer M, Wieland WF, Ruemmele P, Hartmann A, Stoehr R.

Pathobiology. 2014;81(2):53-9. doi: 10.1159/000355976. Epub 2013 Nov 9.

49.

ITCH deficiency protects from diet-induced obesity.

Marino A, Menghini R, Fabrizi M, Casagrande V, Mavilio M, Stoehr R, Candi E, Mauriello A, Moreno-Navarrete JM, Gómez-Serrano M, Peral B, Melino G, Lauro R, Fernandez Real JM, Federici M.

Diabetes. 2014 Feb;63(2):550-61. doi: 10.2337/db13-0802. Epub 2013 Oct 29.

50.

Role of two single nucleotide polymorphisms in secreted frizzled related protein 1 and bladder cancer risk.

Rogler A, Hoja S, Socher E, Nolte E, Wach S, Wieland W, Hofstädter F, Goebell PJ, Wullich B, Hartmann A, Stoehr R.

Int J Clin Exp Pathol. 2013 Sep 15;6(10):1984-98. eCollection 2013.

Supplemental Content

Loading ...
Support Center